Lubiprostone
Overview
Lubiprostone is a chloride channel activator used in the treatment of chronic idiopathic constipation, opioid-induced constipation, and irritable bowel syndrome with constipation. It increases intestinal fluid secretion, thereby improving fecal transit.
API suppliers (10)
Suppliers of Lubiprostone evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.
Country recorded for 7 of 10 suppliers.
6 of 10 hold a GMP certificate on record in the EU or UK registers
- DR REDDYS LABORATORIES LTD1 active DMF GMP on record
- MSN Laboratories Private LimitedIndia1 active DMF GMP on record
- YS LIFE SCIENCE CO LTD1 active DMF
- EVERLIGHT CHEMICAL INDUSTRIAL CORPTaiwan1 active DMF
- Zhejiang Ausun Pharmaceutical Co., Ltd.China1 active DMF GMP on record
- Apotex Pharmachem India Pvt. Ltd.India1 active DMF
- Sun Pharmaceutical Industries LimitedIndia1 active DMF GMP on record
- APOTEX PHARMACHEM INC
- Teva Pharmaceutical Industries Ltd.Israel GMP on record
- FIS FABBRICA ITALIANA SINTETICI SPAItaly GMP on record
Patent & exclusivity (US)
Per the FDA Orange Book (12 approved US products), the latest listed US patent on Lubiprostone expires 25 Oct 2027. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Do you supply Lubiprostone? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.